Nocturnal home hemodialysis and its impact on erythropoietin responsiveness

Clinical Nephrology

Volumn 74, Issue 3, 2010, Pages 167-172

  Rioux, J P ^a   Chan, C T ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anemia; Bone marrow; Erythropoietin responsiveness; Nocturnal hemodialysis

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; TOXIN;

ANEMIA; BIOLOGY; BIOSYNTHESIS; CLINICAL ASSESSMENT; ENVIRONMENTAL FACTOR; ERYTHROCYTE; HEMATOPOIETIC STEM CELL; HOME DIALYSIS; HUMAN; INFLAMMATION; KIDNEY CLEARANCE; NIGHT; REVIEW; TREATMENT RESPONSE; UREMIA; BLOOD; COMPLICATION; KIDNEY FAILURE, CHRONIC; PROCEDURES;

ANEMIA; CYTOKINES; ERYTHROPOIETIN; HEMODIALYSIS, HOME; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 77957141099     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74167     Document Type: Review

References (37)

1. + hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997; 185: 111-120.
2. Allen DA, Breen C, Yagoob MM, Macdougall. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med. 1999; 47: 204-211.
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590.
4. Brox AG, Zhang F, Guyda H, Gagnon RF. Sub-therapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse. Kidney Int. 1996; 50: 937-943.
5. Broxmeyer HE, Kohli L, Kim CH, Lee Y, Mantel C, Cooper S, Hangoc G, Shaheen M, Li X, Clapp DW. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G (alpha) i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol. 2003; 73: 630-638.
6. Caufriez A, Abramowicz D, Vanherweghem JL, Copinschi G. Insulin-like growth factor I values in patients on maintenance hemodialysis: relationship to growth hormone and albumin levels. J Endocrinol Invest. 1993; 16: 691-696.
7. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002; 61: 2235-2239.
8. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003; 42: 925-931.
9. Chan CT, Liu PP, Arab S, Jamal N, Messner HA. Nocturnal hemodialysis improves erythropoietin responsiveness and growth of hematopoietic stem cells. J Am Soc Nephrol. 2009; 20: 665-671.
10. Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulinlike growth factor 1. Blood. 1991; 78: 2823-2833.
11. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.
12. Fouque D. Insulin-like growth factor 1 resistance in chronic renal failure. Miner Electrolyte Metab. 1996; 22: 133-137.
13. Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, Caramelo C. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998; 54: 1337-1343.
14. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med. 2001; 344: 102-107.
15. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996; 334: 420-425.
16. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1077-1083.
17. Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: what is the evidence base? Nephrol Dial Transplant. 2003; 18 (Suppl): 29-35.
18. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004; 44: 715-719.
19. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999; 10: 610-619. (Pubitemid 29117643)
20. Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int. 2001; 78 (Suppl): 67-72.
21. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997; 8: 19211929.
22. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998; 53: 1399-1404.
23. Nakao K, Wada J, Ota K, Ichikawa H, Akagi S, Okamoto A, Hida K, Nagake Y, Makino H. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients. Am J Kidney Dis. 2003; 41: 624-636.
24. Nissenson AR, Nimer SD, Wolcott DL. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med. 1991; 114: 402-416.
25. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999; 283: 845-848.
26. Rabbany SY, Heissig B, Hattori K Rafii S. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med. 2003; 9: 109-117.
27. Radtke HW, Rege AB, LaMarche MB, Bartos D, Bartos F, Campbell RA, Fisher JW. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest. 1981; 67: 1623-1629.
28. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993; 328: 171-175.
29. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Hematol. 1987; 67: 11-17.
30. Schwartz DI, Pierratos A, Richardson RM, Fenton SS, Chan CT. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol. 2005; 63: 202-208.
31. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000; 15: 1207-1211.
32. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity-ESRD-patients converted from conventional to short daily hemodialysis. Am J Kidney Dis. 2003; 42: 1020-1035.
33. Uldall R, Ouwendyk M, Francoeur R, Wallace L, Sit W, Vas S, Pierratos A. Slow nocturnal home hemodialysis at the Wellesley Hospital. Adv Ren Replace Ther. 1996; 3: 133-136. (Pubitemid 26112689)
34. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol. 1999; 10: 1815-1823.
35. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999; 10: 1309-1316. (Pubitemid 29246997)
36. Yamada S, Kataoka H, Kobayashi H, Ono T, Minakuchi J, Kawano Y. Identification of an erythropoietic inhibitor from the dialysate collected in the hemodialysis with PMMA membrane (BK-F). Contrib Nephrol. 1999; 125: 159-172.
37. Yuen D, Richardson RM, Fenton SS, McGrath- Chong ME, Chan CT. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. Asaio J. 2005; 51: 236-241.